WTVT, the Tampa Bay Area Fox station, featured the PULs Cardiac Test, a blood test that can identify patients showing no symptoms with silent underlying coronary artery disease who are at risk for a heart attack and in whom early intervention can improve outcomes.
PULs, an acronym for Protein Unstable Lesion Signature, measures key proteins secreted from a patient’s damaged artery. The result of the measurements helps physicians determine if a person has underlying heart disease and provides an estimate as to how likely a heart attack is over the next 5 years.
“This heart test allows us to identify people at an extremely early stage,” says GD Biosciences founder and test developer Dr. Douglas Harrington during his interview with WTVT Fox’s Dr. Joette Giovinco. “Now, [those at risk] have plenty of time to correct it.”
One such at-risk patient, Ray Behfooroz, appeared in the segment, crediting his life to the PULs Cardiac Test after being “shocked” to learn that he had a high PULs score and that one of his main arteries was almost 100 percent and a heart attack was imminent.
Ray avoided a heart attack, but other patients like Ray, who had normal cholesterol and cardiac stress tests are not so lucky.
One patient, James, was scheduled to receive an immediate stent procedure after learning of his elevated PULs test score. Despite the immediacy, James experienced a heart attack the day before his scheduled stenting. Fortunately, his knowledge of being high risk for a heart attack resulted in a rapid trip to the Emergency Room, improving his outcome.
Watch the Fox 13 Tampa segment on YouTube: https://www.youtube.com/watch?v=cel0l0Xyvcs
Unlike most other heart attack tests, the PULs Test does not focus on cholesterol. According to research published by multiple independent researchers, up to 50 percent of all heart attack victims show normal cholesterol levels.
“Our goal is to identify those people who continually get a clean bill of health after their regular check-up,” continued Dr. Harrington. “Next thing you know, they walk out the door and drop dead of a heart attack, leaving people to scratch their heads and ask, well, why did that happen?”
The new heart test is currently in various test markets throughout the United States. According to data to be presented by Dr. Harrington at the International Academy of Cardiology in July, 60 percent of PULs Test takers needed their treatment plans altered by their physicians.
About Douglas Harrington, MD
Dr. Douglas Harrington has over 30 years of experience in the research, development, commercialization, and expansion of innovative healthcare technology and services. As former President and Lab Director of Nichols Institute, Dr. Harrington expanded their molecular genetics, infectious disease, immunology, cytogenetic, and anatomic pathology offerings.
Dr. Harrington holds a number of patents including automated image analysis of residual cancer protein, catalytic heavy metal extraction, and biomarker assays for diagnosis and classification of cardiac disease. He has been involved as director or founder of multiple startup companies – from devices to molecular genetics focusing on immunology, cancer and cardiology, where he has taken a number of new molecular technologies through state and federal regulatory approval.
In addition to being the CEO & Lab Director of Global Discovery Biosciences (GD Biosciences), Dr. Harrington is a Clinical Professor of Pathology at the USC Keck School of Medicine, a published author of numerous peer-reviewed papers, and a sought after speaker in the area of preventive medicine.
About GD Biosciences
Global Discovery Biosciences is a pioneer in the field of diagnostic medicine. The company works on the cutting edge of medical research, turns discoveries into innovative products and brings those products to the global marketplace.
The company works with advanced research teams to develop, manufacture and distribute innovative technology platforms to address the needs of the global disease burden. Its CLIA-certified and GMP laboratory performs a menu of clinically effective tests targeting key health issues. Our goal is to equip physicians with the tools they need to transform health care – one patient at a time.
SOURCE: GD Biosciences
This press release is distributed by PR NewsChannel. Your News. Everywhere.